Australian regulator TGA warns of ‘rare but severe’ eye disorder linked to GLP-1 drugs like Ozempic
Illustration
AI Summary
TGA says product information for some diabetes and weight loss drugs updated with warning of NAION disorder Follow our Australia news live blog for latest updates Get our breaking news email, free app or daily news podcast Australia’s medicines regulator has issued warnings for several type 2 diabetes and obesity-related treatments – including Ozempic and Mounjaro – over the potential to cause a “rare but severe” eye disorder that could lead to blindness. Newsiline summarises this report from The Guardian Australia and links readers to the original publisher for the full story.
Key Points
- Original report published by The Guardian Australia.
- Newsiline stores only headline metadata, source credit, and a short summary.
- Readers are directed to the publisher for the complete article.
Why It Matters
This story may affect readers following the category, country, or source involved. Newsiline keeps the summary neutral and points to the publisher for full context.
Sources
The Guardian Australia: Read full story at source
Newsiline provides short summaries and links to publishers. It does not republish full articles.